Johnson & Johnson (JNJ)

[winston]

not vested

Johnson & Johnson (JNJ): This Long-Term Titan Is Unstoppable

Long-term investors like JNJ stock because it has a strong brand-name, solid financials and a great product portfolio

By Laura Hoy

Source: Investor Place

http://investorplace.com/2016/05/johnso ... zvdPJF96M8

[winston]

Health care giant Johnson & Johnson touches a fresh all-time high.

[winston]

JNJ Stock: Johnson & Johnson Can’t Walk the Long-Term Walk

Buying JNJ stock now may represent a significant opportunity cost

By James Brumley

Source: Investor Place

http://investorplace.com/2016/06/johnso ... 2S4_rh96M8

[winston]

THE LONG-TERM UPTREND IN EVERYDAY PRODUCTS

It isn't "exciting," but it works...

That's the theme of today's Market Notes. And perhaps no company has more products in your house than Johnson & Johnson (JNJ). The company makes diaper-rash relief Desitin, hair-growth treatment Rogaine, Band-Aid bandages, Listerine mouthwash, Tylenol pain relief, Visine eye drops, and countless other brands that are likely in your medicine cabinet.

One of the world's largest consumer-health-product companies, Johnson & Johnson has been a household staple for 130 years. It owns more than 265 companies across 60-plus countries and has around 125,000 employees.

Due to its incredible number of products, Johnson & Johnson generates safe, reliable returns year after year. And it passes much of that along to its shareholders. It has increased its dividend every year for the last 54 years.

Over the last four years, Johnson & Johnson has also seen big gains in its share price. Shares are up nearly 75% over the last four years, and recently hit a new multidecade high. It's a bull market for this blue-chip dividend-payer...

Source: Daily Wealth

[winston]

Buying the basics works… Consumer-products maker Johnson & Johnson touches a new 52-week high.

[winston]

not vested

Stellar Dow Jones Stocks #4: Johnson & Johnson (JNJ)

Year-to-Date Performance: 20%

Johnson & Johnson (NYSE:JNJ) is up 20% for the year-to-date and its price momentum is accelerating. Few saw that coming after it had such a disappointing 2015.

Sure, as a healthcare company, JNJ benefits from gains in the broader sector and well long-term demographic trends. But the attraction rightfully comes down to its solid profit growth in the midst of an earnings recession … and a lack of alternatives.

Bonds are so ugly that investors are forced to embrace more defensive equities.

Medical devices, pharmaceuticals and consumer staples are better equipped to withstand global sluggishness and any impact from the Brexit. With such a widely diversified portfolio, JNJ offers more protection than many sector names.

Source: Investor Place

[winston]

not vested

Stocks to Buy for the Next 50 Years: Johnson & Johnson (JNJ)

Fifty years from now, unless Leonard McCoy’s medical tricorder from Star Trek becomes a reality, we’re still going to need Band-Aids. And I’m betting that Johnson & Johnson (NYSE:JNJ) is there to deliver them.

Johnson & Johnson is going to rank pretty high on any list of stocks to buy for the next 50 years. It meets all the criteria you would want to have in place.

Most of its consumer and medical products are cheap and disposable … the sort of stuff you buy on a quick pharmacy run and just sort of take for granted.

Of course, JNJ is more than just Band-Aids — it has thriving medical devices and pharmaceutical businesses as well. But all of these businesses have one thing in common: None are particularly dependent on a strong economy.

JNJ is one of the most defensive stocks out there, and one of only two AAA-rated companies left in America. And the other — Microsoft Corporation (NASDAQ:MSFT) — is under review and may not be AAA much longer.

Johnson & Johnson has raised its dividend for 54 consecutive years and counting. And I’m betting it will still be raising it 50 years from now.

Source: Investor Place

[winston]

not vested

There’s More to Johnson & Johnson (JNJ) Than Meets the Eye

The iconic company isn't the dinosaur some are making it out to be

By James Brumley

Source; Investor Place

http://investorplace.com/2016/08/johnso ... 8ZBcJh96M8

[winston]

not vested

Does Baby Powder Cause Cancer? Another Jury Says Yes.

Source: Associated Press

http://www.theepochtimes.com/n3/2178696 ... -says-yes/

[winston]

not vested

Trade of the Day: Johnson & Johnson (JNJ) a Healthy Investment

Johnson & Johnson looks ready to push another leg higher

By Sam Collins

Last November, it received FDA approval for a breakthrough therapy to treat double refractory myeloma. European approval was received in May 2016. Further, management believes it will have 10 new drugs from 2015 to 2019, each with the potential to achieve $1 billion in annual sales.

Restructuring of its medical device unit, announced in January 2016, is expected to save $800 million to $1 billion by 2018.

Standard & Poor’s estimates 2016 and 2017 EPS of $6.73 and $7.01 and has a target price of $143 which is 20.7X their forward 12-month estimate of $6.90.

Thus, buy JNJ at $116 with the assumption that it will break through resistance and achieve a trading target of $135 for a proposed gain of 16% plus dividends.

Source: Investor Place

http://investorplace.com/2016/11/johnso ... DAxMvl96M8